Sprint Precision Technologies
688605
Jiangsu Jingxue Insulation Technology
301010
Global Infotech
300465
Hydsoft Technology
301316
SGSG Science&Technology
300561
CN Stock MarketDetailed Quotes
300247 Youngy Health
- 4.55
- +0.17+3.88%
Market Closed Dec 12 15:00 CST
3.66BMarket Cap98.91P/E (TTM)
4.66High4.33Low518.82KlotVolume4.37Open4.38Pre Close234.15MTurnover6.46%Turnover Ratio137.88P/E (Static)804.04MShares4.8852wk High3.48P/B3.65BFloat Cap2.2452wk Low5.26Limit Up803.28MShs Float12.94Historical High3.50Limit Down7.53%Amplitude1.16Historical Low--Dividend TTM4.51Avg Price217.11KlotAsk--Div YieldTTM100Lot Size294.27KlotBid
Youngy Health Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 27.16%475.8M | 22.93%333.38M | 11.42%176.33M | 14.27%529.45M | 13.16%374.17M | 14.85%271.2M | 28.43%158.26M | -12.00%463.32M | -10.09%330.66M | -12.02%236.14M |
| Operating revenue | 27.16%475.8M | 22.93%333.38M | 11.42%176.33M | 14.27%529.45M | 13.16%374.17M | 14.85%271.2M | 28.43%158.26M | -12.00%463.32M | -10.09%330.66M | -12.02%236.14M |
| Other operating revenue | ---- | 7.48%38.83M | ---- | -19.46%7.68M | ---- | 29.49%36.13M | ---- | -6.45%9.53M | ---- | 683.88%27.9M |
| Total operating cost | 26.11%421.22M | 21.11%286.97M | 5.48%144.83M | 3.78%481.04M | 5.08%334.01M | 7.43%236.95M | 29.93%137.31M | -10.13%463.52M | -11.33%317.87M | -15.18%220.56M |
| Operating cost | 29.82%329.08M | 24.79%226.71M | 9.31%121.65M | 0.97%355.47M | 2.45%253.49M | 6.24%181.67M | 39.72%111.29M | -11.83%352.04M | -11.37%247.42M | -16.78%170.99M |
| Operating tax surcharges | 35.67%4.31M | 39.98%3.42M | 43.31%1.81M | 4.24%4.82M | -18.94%3.18M | -14.14%2.44M | -13.81%1.27M | 16.97%4.63M | 25.55%3.92M | 35.29%2.84M |
| Operating expense | 16.65%39.53M | 8.73%25.62M | 5.87%11.29M | 10.77%61.54M | 8.30%33.89M | 13.63%23.56M | 6.65%10.66M | 23.44%55.56M | -5.41%31.29M | -9.38%20.74M |
| Administration expense | 3.50%48.04M | 1.62%33.88M | -4.86%11.36M | 17.21%58.01M | 19.82%46.41M | 27.61%33.34M | -0.06%11.94M | -5.63%49.49M | 20.46%38.74M | 21.09%26.13M |
| Financial expense | 15.28%-8.05M | 0.32%-7.96M | -4,635.63%-3.65M | 14.20%-7.87M | 16.66%-9.51M | -41.99%-7.98M | 230.79%80.57K | -701.74%-9.17M | -1,242.54%-11.41M | -459.42%-5.62M |
| -Interest Income (Financial expense) | ---- | ---- | -121.33%-2.97M | ---- | ---- | ---- | -124.28%-1.34M | ---- | ---- | -745.87%-1.36M |
| Research and development | 26.97%8.31M | 35.46%5.31M | 14.70%2.37M | -17.40%9.06M | -17.17%6.55M | -28.55%3.92M | -22.55%2.07M | -18.86%10.97M | -20.72%7.9M | -14.87%5.48M |
| Credit Impairment Loss | -159.04%-593.29K | -122.14%-203K | 1,264.46%407.01K | -67.91%526.82K | -55.94%1M | -36.94%916.93K | -104.52%-34.95K | -84.58%1.64M | -72.37%2.28M | -76.99%1.45M |
| Asset Impairment Loss | 101.05%47.61K | 100.49%13.98K | 280.58%1.08K | -162.53%-7.56M | -14,795.63%-4.51M | -10,311.70%-2.85M | 82.83%-598.23 | 68.06%-2.88M | -19.49%-30.31K | 91.84%-27.34K |
| Other net revenue | 16.16%11.06M | 11.63%7.09M | 23.29%5.28M | -91.98%11.01M | -93.29%9.53M | -95.29%6.35M | 154.18%4.28M | 398.77%137.36M | 333.48%141.94M | 1,343.97%134.9M |
| Fair value change income | -25.76%8.16M | -16.06%6.07M | 2.13%3.99M | 293.91%13.32M | 113.33%10.99M | 208.33%7.23M | 961.74%3.9M | -78.69%3.38M | -63.60%5.15M | 47.79%2.35M |
| Invest income | 34.79%2.53M | -19.46%561.64K | -35.00%230.55K | -97.02%3.96M | -98.59%1.87M | -99.46%697.35K | 49.00%354.72K | 1,735.96%133.15M | 1,393.25%132.7M | 11,115.78%129.91M |
| Asset deal income | 108.71%35.58K | 93.62%-7.45K | -132.78%-5.38K | -184.83%-497.92K | -173.37%-408.38K | -126.54%-116.82K | --16.42K | 2,135.76%586.97K | 428,413.87%556.6K | 7,107.23%440.15K |
| Other revenue | 52.89%892.33K | 39.96%648.34K | 1,588.75%654.67K | -14.88%1.26M | -54.46%583.63K | -40.27%463.23K | -87.38%38.77K | -46.29%1.49M | -13.50%1.28M | 25.39%775.56K |
| Operating profit | 32.13%65.65M | 31.75%53.49M | 45.76%36.78M | -56.68%59.42M | -67.89%49.68M | -73.02%40.6M | 31.16%25.23M | 258.20%137.16M | 268.10%154.73M | 749.45%150.47M |
| Add:Non operating Income | -39.55%358.43K | -63.81%8.21K | -94.96%3.57K | 366.73%1.1M | 187.50%592.89K | -88.30%22.68K | -55.88%70.79K | 54.00%235.65K | 43.18%206.22K | 123.22%193.87K |
| Less:Non operating expense | -20.00%141.53K | -5.78%75K | 1,366.09%28.18K | -24.16%764.7K | -82.15%176.91K | -9.15%79.61K | -86.58%1.92K | 48.44%1.01M | 5,567.50%991.32K | 472.92%87.62K |
| Total profit | 31.47%65.86M | 31.77%53.43M | 45.27%36.76M | -56.19%59.76M | -67.46%50.1M | -73.07%40.54M | 30.53%25.3M | 261.14%136.39M | 265.13%153.95M | 746.63%150.58M |
| Less:Income tax cost | 37.87%15.73M | 55.86%13.24M | 22.38%8.54M | 482.59%17.84M | 47.80%11.41M | 6.87%8.49M | -0.51%6.97M | -51.53%3.06M | 37.50%7.72M | 79.41%7.95M |
| Net profit | 29.58%50.14M | 25.39%40.19M | 53.98%28.22M | -68.56%41.92M | -73.54%38.69M | -77.53%32.05M | 48.11%18.33M | 323.95%133.33M | 300.09%146.23M | 967.98%142.63M |
| Net profit from continuing operation | 29.58%50.14M | 25.39%40.19M | 53.98%28.22M | -68.56%41.92M | -73.54%38.69M | -77.53%32.05M | 48.11%18.33M | 323.95%133.33M | 300.09%146.23M | 967.98%142.63M |
| Less:Minority Profit | 5.34%13.7M | 4.54%11.51M | 3.59%7.39M | 118.47%15.34M | 61.29%13M | 34.65%11.01M | -1.02%7.14M | -3.12%7.02M | 28.05%8.06M | 79.31%8.18M |
| Net profit of parent company owners | 41.84%36.44M | 36.30%28.68M | 86.12%20.83M | -78.95%26.58M | -81.41%25.69M | -84.35%21.04M | 116.73%11.19M | 421.87%126.31M | 356.71%138.17M | 1,428.73%134.45M |
| Earning per share | ||||||||||
| Basic earning per share | 42.01%0.0453 | 36.26%0.0357 | 86.33%0.0259 | -81.25%0.03 | -81.43%0.0319 | -84.33%0.0262 | 117.19%0.0139 | 433.33%0.16 | 356.91%0.1718 | 1,433.94%0.1672 |
| Diluted earning per share | 42.01%0.0453 | 36.26%0.0357 | 86.33%0.0259 | -81.25%0.03 | -81.43%0.0319 | -84.33%0.0262 | 117.19%0.0139 | 433.33%0.16 | 356.91%0.1718 | 1,433.94%0.1672 |
| Other composite income | -173.87%-3.57M | -96.25%236.98K | -78.86%-2.72M | -94.13%2.01M | -89.30%4.83M | -83.52%6.32M | -818.85%-1.52M | 2,185.04%34.33M | 1,576.12%45.19M | 824.48%38.33M |
| Other composite income of parent company owners | -188.46%-2.32M | -96.25%154.03K | -78.86%-1.77M | -95.80%1.31M | -93.55%2.62M | -88.67%4.1M | -497.25%-986.92K | 3,016.67%31.22M | 1,429.31%40.7M | 1,153.70%36.24M |
| Other composite income of minority owners | -156.55%-1.25M | -96.25%82.94K | -78.86%-950.5K | -77.36%705.21K | -50.82%2.21M | 5.56%2.21M | ---531.42K | 640.59%3.12M | --4.49M | 213.07%2.09M |
| Total composite income | 6.98%46.56M | 5.36%40.42M | 51.73%25.5M | -73.80%43.93M | -77.26%43.53M | -78.80%38.37M | 37.68%16.81M | 462.57%167.66M | 471.61%191.42M | 2,144.02%180.96M |
| Total composite income of parent company owners | 20.50%34.12M | 14.66%28.83M | 86.82%19.06M | -82.29%27.89M | -84.17%28.31M | -85.27%25.14M | 104.15%10.2M | 580.96%157.53M | 557.79%178.86M | 3,086.92%170.69M |
| Total composite income of minority owners | -18.18%12.45M | -12.31%11.59M | -2.46%6.44M | 58.27%16.04M | 21.16%15.21M | 28.72%13.22M | -8.39%6.61M | 51.96%10.14M | 99.43%12.56M | 279.24%10.27M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | China Securities Tiantong Certified Public Accountants (Special General Partnership) | -- | -- | -- | China Securities Tiantong Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
